Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Merit Medical (MMSI) to $117 from $120 and keeps an Overweight rating on the shares. The firm notes the company reported Q4 results in line with its Jan preannounce and EPS “nicely” ahead of consensus. Merit Medical also issued 2025 guidance, with organic sales growth above consensus but EPS below due to higher interest expense and dilution related to convertible debt.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Strong Financial Performance and Strategic Execution Drive Buy Rating for Merit Medical Systems
- Merit Medical Reports Strong 2024 Financial Results
- Merit Medical Systems Reports Strong 2024 Financial Results
- Merit Medical sees FY25 EPS $3.58-$3.70, consensus $3.74
- Merit Medical reports Q4 EPS 93c, consensus 83c